Exicure, Inc. Files 8-K for Material Definitive Agreement

TL;DR

EXICURE (XCUR) filed an 8-K on Jan 19 for a material definitive agreement. Details to follow.

AI Summary

On January 19, 2025, Exicure, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits. Exicure, Inc. is incorporated in Delaware and its principal executive offices are located in Chicago, IL.

Why It Matters

This 8-K filing indicates a significant new agreement for Exicure, Inc., which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could involve significant financial or operational changes, but the specific details and implications are not yet fully disclosed.

Key Numbers

• 001-39011 — SEC File Number (Identifies Exicure, Inc.'s filing with the SEC.)
• 81-5333008 — IRS Employer Identification No. (Tax identification number for Exicure, Inc.)

Key Players & Entities

• Exicure, Inc. (company) — Registrant
• January 19, 2025 (date) — Date of earliest event reported
• 2430 N. Halsted St. Chicago, IL 60614 (location) — Principal Executive Offices
• Max-1 Acquisition Corp (company) — Former Company Name

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share XCUR The Nasdaq Stock Market
• $0.27 — ion shares outstanding at approximately $0.27 per share million. In connection with

Filing Documents

• xcur-20250119.htm (8-K) — 27KB
• ex991pressrelease12225.htm (EX-99.1) — 12KB
• exicureimage1a10.gif (GRAPHIC) — 3KB
• 0001698530-25-000004.txt ( ) — 168KB
• xcur-20250119.xsd (EX-101.SCH) — 2KB
• xcur-20250119_lab.xml (EX-101.LAB) — 21KB
• xcur-20250119_pre.xml (EX-101.PRE) — 12KB
• xcur-20250119_htm.xml (XML) — 3KB

01 Entry Into a Material Definitive Agreement

Item 1.01 Entry Into a Material Definitive Agreement On January 19, 2025, Exicure Inc. ("the Company") entered into a Share Purchase Agreement with GPCR Therapeutics Inc, a Korean corporation, ("GPCR") pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation ("GPCR USA"). The transactions contemplated under the Share Purchase Agreement closed concurrently with execution. GPCR USA was, until immediately prior to closing under the Share Purchase Agreement, a wholly owned subsidiary of GPCR. The Company purchased GPCR USA's six million shares outstanding at approximately $0.27 per share million. In connection with the closing of the Share Purchase Agreement, the Company and GPCR entered into a License and Collaboration Agreement ("L&C Agreement") to further develop and commercialize GPCR's technologies related to certain intellectual property and patents. The L&C Agreement requires the Company to make milestone payments to GPCR upon the achievement of specific milestone events relating to clinical trials, marketing authorizations, and net sales, as well as for the Company to pay a recurring royalty payment based on 10% of net sales, as set forth in the L&C Agreement. There is no material relationship between the parties other than with respect to the agreements disclosed in the 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated January 22, 2025 104 Cover Page Interactive Data File (Embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 22, 2025 EXICURE, INC. (registrant) By: /s/ Andy Yoo Andy Yoo Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR